Impact of left venticular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes

David L. Joyce, Robert E. Southard, Guillermo Torre-Amione, George P. Noon, Geoffrey A. Land, Matthias Loebe

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Humoral sensitization, defined as a panel-reactive antibody (PRA) screen of >10%, places heart transplant recipients at a greater risk of acute rejection and mortality. Previous studies have suggested an increased sensitization in left ventricular assist device (LVAD) recipients, although neither the impact of device selection nor the clinical importance of elevated PRA in these patients has been completely described. Methods: Using the registry of the International Society for Heart and Lung Transplantation (ISHLT), we compared PRA levels in 7,686 heart transplant recipients to determine the impact of LVAD therapy on humoral sensitization, acute rejection and mortality. To determine the impact of device selection on sensitization, we compared data from the ISHLT registry as well as from our own institution. Results: Elevated PRA levels were found in 16.6% of LVAD recipients, compared with 7.6% of non-LVAD controls (p < 0.0001). Sensitization differed by device type, being present in 21.9% of Thoratec recipients, 14.4% of HeartMate recipients, and 15.5% of Novacor recipients (p = 0.01). Despite these findings, LVAD use had no impact on rejection rates. LVAD use was associated with a small increase (4.4% and 4.3%, respectively) in 1- and 2-year mortality. Conclusions: These findings support the concept that mechanical circulatory support increases the rate of humoral sensitization. However, these differences in sensitization do not translate to substantial differences in the clinical outcomes of rejection and mortality.

Original languageEnglish (US)
Pages (from-to)2054-2059
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume24
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Transplants
Equipment and Supplies
Mortality
Antibodies
Registries
Mechanical Phenomena
Heart-Lung Transplantation
Heart-Assist Devices
Transplant Recipients

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Impact of left venticular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. / Joyce, David L.; Southard, Robert E.; Torre-Amione, Guillermo; Noon, George P.; Land, Geoffrey A.; Loebe, Matthias.

In: Journal of Heart and Lung Transplantation, Vol. 24, No. 12, 12.2005, p. 2054-2059.

Research output: Contribution to journalArticle

Joyce, David L. ; Southard, Robert E. ; Torre-Amione, Guillermo ; Noon, George P. ; Land, Geoffrey A. ; Loebe, Matthias. / Impact of left venticular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. In: Journal of Heart and Lung Transplantation. 2005 ; Vol. 24, No. 12. pp. 2054-2059.
@article{e9c6b37c4fce4d3f9a11c9ae4f815aa9,
title = "Impact of left venticular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes",
abstract = "Background: Humoral sensitization, defined as a panel-reactive antibody (PRA) screen of >10{\%}, places heart transplant recipients at a greater risk of acute rejection and mortality. Previous studies have suggested an increased sensitization in left ventricular assist device (LVAD) recipients, although neither the impact of device selection nor the clinical importance of elevated PRA in these patients has been completely described. Methods: Using the registry of the International Society for Heart and Lung Transplantation (ISHLT), we compared PRA levels in 7,686 heart transplant recipients to determine the impact of LVAD therapy on humoral sensitization, acute rejection and mortality. To determine the impact of device selection on sensitization, we compared data from the ISHLT registry as well as from our own institution. Results: Elevated PRA levels were found in 16.6{\%} of LVAD recipients, compared with 7.6{\%} of non-LVAD controls (p < 0.0001). Sensitization differed by device type, being present in 21.9{\%} of Thoratec recipients, 14.4{\%} of HeartMate recipients, and 15.5{\%} of Novacor recipients (p = 0.01). Despite these findings, LVAD use had no impact on rejection rates. LVAD use was associated with a small increase (4.4{\%} and 4.3{\%}, respectively) in 1- and 2-year mortality. Conclusions: These findings support the concept that mechanical circulatory support increases the rate of humoral sensitization. However, these differences in sensitization do not translate to substantial differences in the clinical outcomes of rejection and mortality.",
author = "Joyce, {David L.} and Southard, {Robert E.} and Guillermo Torre-Amione and Noon, {George P.} and Land, {Geoffrey A.} and Matthias Loebe",
year = "2005",
month = "12",
doi = "10.1016/j.healun.2005.06.028",
language = "English (US)",
volume = "24",
pages = "2054--2059",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - Impact of left venticular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes

AU - Joyce, David L.

AU - Southard, Robert E.

AU - Torre-Amione, Guillermo

AU - Noon, George P.

AU - Land, Geoffrey A.

AU - Loebe, Matthias

PY - 2005/12

Y1 - 2005/12

N2 - Background: Humoral sensitization, defined as a panel-reactive antibody (PRA) screen of >10%, places heart transplant recipients at a greater risk of acute rejection and mortality. Previous studies have suggested an increased sensitization in left ventricular assist device (LVAD) recipients, although neither the impact of device selection nor the clinical importance of elevated PRA in these patients has been completely described. Methods: Using the registry of the International Society for Heart and Lung Transplantation (ISHLT), we compared PRA levels in 7,686 heart transplant recipients to determine the impact of LVAD therapy on humoral sensitization, acute rejection and mortality. To determine the impact of device selection on sensitization, we compared data from the ISHLT registry as well as from our own institution. Results: Elevated PRA levels were found in 16.6% of LVAD recipients, compared with 7.6% of non-LVAD controls (p < 0.0001). Sensitization differed by device type, being present in 21.9% of Thoratec recipients, 14.4% of HeartMate recipients, and 15.5% of Novacor recipients (p = 0.01). Despite these findings, LVAD use had no impact on rejection rates. LVAD use was associated with a small increase (4.4% and 4.3%, respectively) in 1- and 2-year mortality. Conclusions: These findings support the concept that mechanical circulatory support increases the rate of humoral sensitization. However, these differences in sensitization do not translate to substantial differences in the clinical outcomes of rejection and mortality.

AB - Background: Humoral sensitization, defined as a panel-reactive antibody (PRA) screen of >10%, places heart transplant recipients at a greater risk of acute rejection and mortality. Previous studies have suggested an increased sensitization in left ventricular assist device (LVAD) recipients, although neither the impact of device selection nor the clinical importance of elevated PRA in these patients has been completely described. Methods: Using the registry of the International Society for Heart and Lung Transplantation (ISHLT), we compared PRA levels in 7,686 heart transplant recipients to determine the impact of LVAD therapy on humoral sensitization, acute rejection and mortality. To determine the impact of device selection on sensitization, we compared data from the ISHLT registry as well as from our own institution. Results: Elevated PRA levels were found in 16.6% of LVAD recipients, compared with 7.6% of non-LVAD controls (p < 0.0001). Sensitization differed by device type, being present in 21.9% of Thoratec recipients, 14.4% of HeartMate recipients, and 15.5% of Novacor recipients (p = 0.01). Despite these findings, LVAD use had no impact on rejection rates. LVAD use was associated with a small increase (4.4% and 4.3%, respectively) in 1- and 2-year mortality. Conclusions: These findings support the concept that mechanical circulatory support increases the rate of humoral sensitization. However, these differences in sensitization do not translate to substantial differences in the clinical outcomes of rejection and mortality.

UR - http://www.scopus.com/inward/record.url?scp=29144511605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144511605&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2005.06.028

DO - 10.1016/j.healun.2005.06.028

M3 - Article

VL - 24

SP - 2054

EP - 2059

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 12

ER -